Around the world, cardiovascular disease (CVD) is the leading cause of deaths for adults ([@b95-vhrm-4-0991]). The most important modifiable cardiovascular risk factors are smoking, hypertension, dyslipidemia, obesity (mainly central) and hyperglycemia. These risk factors are often clustered, particularly for patients with type 2 diabetes and/or metabolic syndrome. Among dyslipoproteinemia, mixed or combined hyperlipidemia is a common disorder, occurring in about 30% of myocardial infarction (MI) survivors ([@b24-vhrm-4-0991]). Mixed dyslipidemia is characterized by elevated levels of triglycerides (TG) and reduced high-density lipoprotein cholesterol (HDL-C), with or without elevated levels of low-density lipoprotein cholesterol (LDL-C). This atherogenic lipoprotein phenotype is usually associated with a preponderance of small, dense LDL particles and an elevated apolipoprotein B (ApoB) concentration. All the metabolic abnormalities of mixed dyslipidemia contribute to increase risk for CVD. Mixed dyslipidemia can be genetically determined such as in familial combined hyperlipidemia and is also the must frequent lipid disorder found in patients with type 2 diabetes and metabolic syndrome ([@b9-vhrm-4-0991]; [@b85-vhrm-4-0991]). This review updates the management of mixed dyslipidemia and particularly on the clinical utility of fenofibrate in mixed dyslipidemia.

Management of mixed dyslipidemia
================================

Mixed dyslipidemia is usually characterized by elevated LDL-C and TG and decreased HDL-C levels. Although plasma levels of LDL-C may be normal or only slightly above target levels, an increase in atherogenic small, dense LDL is a common feature, as well as elevated non-HDL-C and ApoB levels. Numerous landmark trials involving HMG-CoA reductase inhibitors (statins) have firmly demonstrated that LDL-C lowering significantly reduces total mortality and CVD morbidity and mortality ([@b18-vhrm-4-0991]). Therefore, the use of statins has become the cornerstone of lipid lowering therapy in reducing the risk of CVD. Statins are indicated as first-line therapy for patients for primary hypercholesterolemia and mixed dyslipidemia. Moreover recent trials comparing different statin treatments have shown that intensive LDL-C lowering regimens are significantly more effective than moderate treatments in reducing coronary events and atherosclerotic progression ([@b67-vhrm-4-0991]; [@b13-vhrm-4-0991]).

Elevated LDL-C is identified as the primary target of lipid-lowering therapy by both US ([@b66-vhrm-4-0991]; [@b42-vhrm-4-0991]) and European ([@b27-vhrm-4-0991]; [@b88-vhrm-4-0991]) guidelines. These guidelines specified LDL-C of 100 mg/dL (2.6 mmol/L) as a minimal goal of treatment in high risk patients. For patients at very high risk, a new therapeutic option for LDL-C is below 70 to 80 mg/dL (\<2 mmol/L). The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) recognized both low HDL-C (\<40 mg/dL) and elevated TG (≥150 mg/dL) as markers of increased CVD risk. Beyond lowering LDL-C, the NCEP ATP III introduced a secondary target of therapy, non-HDL-C, in patients with elevated TG. In some studies, non-HDL-C has been reported to be a stronger predictor of CVD risk than LDL-C ([@b20-vhrm-4-0991]; [@b74-vhrm-4-0991]). More recently, in a post hoc analysis of TNT and IDEAL trials ([@b50-vhrm-4-0991]), on-statin treatment levels of non-HDL-C and apolipoprotein B were more closely associated with cardiovascular outcome than LDL-C levels, supporting the use of non-HDL-C as a novel treatment target. The goal for non-HDL-C at any level of risk is 30 mg/dL higher than the LDL-C treatment goal. Thus, in patients with mixed dyslipidemia and very high risk (ie, with CVD and diabetes or the metabolic syndrome ([@b42-vhrm-4-0991]) who have an LDL-C goal of 70 mg/dL, the non-HDL-C goal is 100 mg/dL. The coronary risk is also associated with mildly elevated (150--500 mg/dL) plasma TG level. Very high levels of TG (\>500 mg/dL) are a risk for acute pancreatitis.

In high risk patients with mixed dyslipidemia, an ideal treatment should deal with the global spectrum of the atherogenic lipid triad (high LDL-C, low HDL-C and high TG). High levels of LDL-C could be effectively controlled with a statin. However statin therapy may be limited by the failure to reach non-HDL-C goals and sometimes by intolerance or poor response in monotherapy. Several considerations have led to increased interest in non-statin options for correction of mixed dyslipidemia: -- Low HDL-C is associated with increased CVD risk ([@b39-vhrm-4-0991], [@b40-vhrm-4-0991]). The Framingham study indicated a clear relationship between low HDL-C levels and increased risk of coronary disease, irrespective of LDL-C levels ([@b39-vhrm-4-0991]). In a meta-analysis of four large prospective studies ([@b40-vhrm-4-0991]), every 1 mg/dL decrease in HDL-C is associated with increased risk of coronary heart disease (CHD), differently in males and females (2% males and 3% females), independent of other risk factors, including LDL-C levels.-- Even if TG have been a controversial risk factor, recent epidemiologic evidences have demonstrated that elevated TG independently predicts CVD. A recent meta-analysis of 29 prospective studies enrolling 262,525 subjects indicated a strong and highly significant association between TG values and CHD risk ([@b78-vhrm-4-0991]). Two additional studies have corroborated these findings ([@b5-vhrm-4-0991]; [@b68-vhrm-4-0991]), both studies supporting the concept that non-fasting TG levels may strongly predicts the CVD risk ([@b56-vhrm-4-0991]). In mixed dyslipidemia, post-prandial triglyceride-rich lipoproteins are typically increased with a delay in the clearance of these lipoprotein particles and a prolonged exposure.-- Although statins are clearly effective in lowering LDL-C levels, this class of drugs appear to have more modest effects in terms of raising HDL-C and lowering TG. Statins have been reported to raise HDL-C levels by 5% to 15% and to lower TG by 7% to 30% ([@b66-vhrm-4-0991]).-- Finally in landmark statin clinical trials, high "residual" CVD risk can be partly explained by the presence of lipoprotein abnormalities other than LDL. Indeed, subjects treated with a statin but who had low HDL-C levels remained at a greater CVD risk than those with normal or high HDL-C levels. In a recent post-hoc analysis of the Treating to New Targets (TNT) trial, levels of HDL-C were inversely related to the risk of major CVD events among CHD patients receiving statin treatment ([@b6-vhrm-4-0991]). Even in patients with LDL-C at or below the optional treatment target of 70 mg/dL, those who were in the lowest HDL-C quintile had a significantly increased CVD risk compared with those in the highest HDL-C quintile ([@b6-vhrm-4-0991]). Interestingly a similar finding has been found for TG levels in a complementary analysis of PROVE-IT TIMI-22 trial ([@b64-vhrm-4-0991]): compared with individuals who achieved low levels of both LDL-C (\<70 mg/dL) and TG (\<150 mg/dL), patients with higher levels of on-treatment LDL-C and/or TG had significantly elevated risk of CHD events. On-treatment TG \<150 mg/dL was independently associated with a lower risk of recurrent CHD effects.

Conversely, a number of studies have demonstrated that treatment with fibrates or niacin (with or without a statin) improves the atherogenic lipoprotein profile and/or reduces cardiovascular morbidity and mortality. Among these drugs, this review only reports arguments for a clinical utility of fenofibrate.

Mechanism of action of fenofibrate
==================================

Fenofibrate belongs to a class of drugs that exert their effects by activating the peroxisome proliferator-activated receptor α (PPARα), a transcription factor that regulates lipid metabolism via a number of routes. Activated PPARα stimulates the expression of genes encoding various enzymes that regulate fatty acid and lipoprotein metabolism ([@b36-vhrm-4-0991]; [@b33-vhrm-4-0991]; [@b51-vhrm-4-0991]). Fenofibrate stimulated the oxidation of free fatty acids in the liver. This promotion of the β-oxidation of fatty acids reduced the availability of fatty acids for very-low density lipoprotein (VLDL) synthesis and secretion. Fenofibrate also increased the expression of the gene for lipoprotein lipase and decreases ApoC-III expression in the liver. Thus, fenofibrate lowered the concentration of TG both by reducing the rate of synthesis and increasing the rate of hydrolysis of triglyceride-rich lipoproteins ([@b81-vhrm-4-0991]; [@b51-vhrm-4-0991]). Moreover, fenofibrate treatment reduced the proportion of small, dense LDL, with the formation of larger, less dense LDL particles with a higher affinity for the LDL receptor and thus catabolized more rapidly ([@b16-vhrm-4-0991]). PPARα activation with fenofibrate also increased expression of the genes for both ApoA-I and ApoA-II, decreased the cholesteryl ester transfer protein-mediated transfer of cholesterol from HDL to VLDL, enhanced cell cholesterol efflux by induction of cell ABCA1 expression and decreased SR-B1 in the liver. All these effects contribute to the increase of plasma HDL-C concentrations ([@b45-vhrm-4-0991]; [@b17-vhrm-4-0991]; [@b60-vhrm-4-0991]; [@b35-vhrm-4-0991]).

In addition to the lipid-modifying activity, fenofibrate also had numerous pleiotropic effects mediated by PPARα activation ([@b81-vhrm-4-0991]; [@b70-vhrm-4-0991]): fenofibrate improved endothelial function ([@b71-vhrm-4-0991]; [@b14-vhrm-4-0991]; [@b54-vhrm-4-0991]) and exerted anti-inflammatory activities ([@b96-vhrm-4-0991]; [@b76-vhrm-4-0991]) as evidenced by a reduction in CRP as well as a number of cytokines (eg, IL-6, TNF-alpha) In patients with metabolic syndrome and elevated TG, fenofibrate reduced whole blood production of inflammatory cytokines and hepatic-synthesized inflammatory proteins, and the anti-inflammatory effects of fenofibrate involve VLDL- and LDL-mediated pathways ([@b76-vhrm-4-0991]). Fenofibrate also decreased procoagulant factors such as fibrinogen and plasminogen activator inhibitor-1 ([@b49-vhrm-4-0991]; [@b59-vhrm-4-0991]) and reduced monocyte chemoattractant protein-1 ([@b52-vhrm-4-0991]; [@b70-vhrm-4-0991]). Among fibrates, only fenofibrate significantly reduced uric acid levels ([@b55-vhrm-4-0991]; [@b52-vhrm-4-0991]).

In contrast, fenofibrate therapy induced two potential deleterious effects: an increase in creatinine ([@b52-vhrm-4-0991]; [@b90-vhrm-4-0991]) and homocysteine levels ([@b52-vhrm-4-0991]; [@b23-vhrm-4-0991]). Whether these effects on creatinine and homocysteine are of clinical importance remains to be determined. Creatinine rises was not associated with an alteration in renal function, as measured by glomerular filtration rate ([@b47-vhrm-4-0991]). The creatinine elevation associated with fenofibrate treatment is fully reversible within a few weeks of ceasing therapy ([@b87-vhrm-4-0991]), also suggesting an absence of permanent renal damage.

The potential of monotherapy with fenofibrate in the treatment of patients with primary dyslipidemia has been well established in numerous, placebo-controlled and comparative trials ([@b1-vhrm-4-0991]; [@b52-vhrm-4-0991]). The effect of fenofibrate on the concentration of plasma lipids is largely influenced by the baseline lipid levels. Fenofibrate therapy was consistently associated with a substantial decreases of serum TG by 20% to 50%, usually directly proportional to the baseline TG levels. Fenofibrate increased HDL-C levels by 10% to 25%, to a degree directly dependent of baseline TG and HDL-C levels. Fenofibrate had widely variable effects on LDL-C levels mainly dependent of the type of dylipidemia. For example, fenofibrate may decrease LDL-C by 20% in patients with normal TG levels, but generally produces less reduction in LDL-C in patients with mixed dyslipidemia. Patients with severe hypertriglyceridemia and low levels of LDL-C may raise their LDL-C levels during fenofibrate treatment, possibly as a result of an accelerated catabolism of triglyceride-rich lipoproteins, leading to an increased LDL conversion and an increased LDL particle size. This increase in LDL size may constitute an antiatherogenic mechanism.

Clinical utility of fenofibrate in mixed dyslipidemia
=====================================================

Clinical efficacy in monotherapy
--------------------------------

A meta-analysis of randomized fibrate trials (1,457 patients receiving fenofibrate) realized across a range of populations, found that fenofibrate decreased LDL-C and TG respectively by 11% and 40% and increased HDL-C by 10% ([@b10-vhrm-4-0991]).

Although the effect of fenofibrate on LDL-C in these studies was variable, it was generally smaller than that achieved with statins. Two recent trials ([@b31-vhrm-4-0991]; [@b32-vhrm-4-0991]) provided data on the efficacy of fenofibrate monotherapy in large populations of patients with mixed dyslipidemia: in these trials, TG decreased by 43.2% and 41.3%, HDL-C increased by 18.8% and 18.2%, LDL-C decreased by 5.5% and 15.7%, and non-HDL-C decreased by 16.2% and 21.0% ([@b31-vhrm-4-0991]; [@b32-vhrm-4-0991]). The effects on ApoB were in agreement with the evolution of non-HDL-C levels: ApoB levels decreased by 15.2% and 20.1%. ApoA-I levels were increased by 8.4% and 10.8% ([@b31-vhrm-4-0991]; [@b32-vhrm-4-0991]). Finally these trials have confirmed a large and significant shift in LDL size with a decrease in the proportion of small, dense LDL during fenofibrate treatment. In summary, fenofibrate has a favorable action on all the lipoprotein abnormalities present in patients with mixed dyslipidemia.

This pattern of mixed dyslipidemia with high TG, low HDL-C and preponderance of small dense LDL is usually observed in type 2 diabetes and metabolic syndrome. Presumably to follow-up on the favorable effects of gemfibrozil treated diabetic patients in Helsinki Heart Study (HHS) and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) study, the potential role of fenofibrate for CVD risk reduction has only been evaluated in type 2 diabetes, but not specifically type 2 diabetic patients with mixed dyslipidemia.

In the Diabetes Atherosclerosis Intervention Study ([@b22-vhrm-4-0991]), 418 diabetic men and women were randomized to fenofibrate or placebo for 3 years. Baseline lipids were LDL-C of 132 mg/dL, TG of 221 mg/dL, and HDL-C of 40 mg/dL. Fenofibrate lowered LDL-C by 6% and TG by 28%, and raised HDL-C by 7%. Fenofibrate slowed the angiographic progression of coronary atherosclerosis: the progression of focal coronary atheroma was 40% less in the fenofibrate group compared with placebo, without significant effect on diffuse atheroma. Interestingly, although the study was not powered to look at clinical events, there was a non significant 23% reduction in CVD events. These effects seemed to be explained not only by the changes in HDL-C, LDL-C and TG levels, but also by a significant increase in LDL particle size ([@b92-vhrm-4-0991]). Additionally, fenofibrate reduced the incidence of microalbuminuria by 54% ([@b3-vhrm-4-0991]). In DAIS, the increase of homocysteine did not alter the beneficial effect of fenofibrate ([@b37-vhrm-4-0991]).

The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) was the first large landmark cardiovascular event-based trial with fenofibrate ([@b87-vhrm-4-0991]). FIELD was a 5-year, randomized, placebo-controlled, double-blind study of the efficacy and safety of fenofibrate 200 mg/day in 9795 type 2 diabetic patients with (22%) or without (78%) previous CVD. Mean baseline lipids were LDL-C of 119 mg/dL, TG of 153 mg/dL, and HDL-C of 43 mg/dL. Unfortunately, only 21% of patients had a marked dyslipidemia defined (for comparison with other fibrates trials) by TG ≥ 200 mg/dL and low HDL-C \<40 mg/dL in men and \<50 mg/dL in women ([@b79-vhrm-4-0991]). At 4 months and study close, fenofibrate decreased respectively TG by 29% and 22%, LDL-C by 12% and 6% and increased HDL-C by 5% and 1%. Fenofibrate treatment did not have a significant effect on the primary end point (CHD death or non-fatal MI) reduced by only 11% (p = 0.16). There was, however, a significant reduction (--11%, p = 0.035) in the secondary end point of total CVD events (a composite of CVD death, MI, stroke, and coronary or carotid revascularization), largely driven by significant reductions in non-fatal MI (--24%, p = 0.01) and coronary revascularization (--21%, p = 0.003). There was a non-significant increase in CHD death in the fenofibrate group. The FIELD investigators also reported a significant 20% reduction of all MI events (p = 0.006) and a significant 38% reduction in the risk of non-traumatic amputations (p = 0.011) with fenofibrate ([@b11-vhrm-4-0991]). Fenofibrate treatment was also associated with significant reductions in the need for retinal laser therapy and decreased progression/increased regression of albuminuria ([@b87-vhrm-4-0991]). The global results of FIELD have been considered as disappointing event if the overall CVD event results were positive in several regards.

Some explanations can be proposed to explain the FIELD results: the higher rate of statin use in the placebo group (36% among placebo patients by close of study versus 19% in the fenofibrate arm) may play a role. Among fenofibrate patients not receiving off-trial lipid treatment, the CVD composite end point was significantly reduced by 19%. The poor effect of fenofibrate in reducing CVD events, more particularly in secondary prevention, could also be explained by the significant increase of homocysteine levels. It has been shown that gemfibrozil increased plasma homocysteine less than fenofibrate ([@b23-vhrm-4-0991]; [@b84-vhrm-4-0991]) and this difference could explain the better clinical benefit of gemfibrozil in the VA-HIT ([@b75-vhrm-4-0991]; [@b77-vhrm-4-0991]) and HHS ([@b34-vhrm-4-0991]). Another hypothesis to explain the FIELD results is the modest effects of fenofibrate on lipid parameters; particularly the declining effect on HDL-C overtime could also be due to the fact to elevated homocysteine has been reported to reduce the ApoA-I expression ([@b63-vhrm-4-0991]).

More convincing, the relative lack of favorable effects in FIELD may be related to the selected population. Fibrates reduce CVD effectively in patients with insulin resistance/overweight people with high TG and low HDL-C ([@b7-vhrm-4-0991]). In FIELD, the baseline TG was lower and the HDL-C was higher than in HHS or VA-HIT, with a lower TG/HDL-C ratio (4.05) than in VA-HIT (higher ratio of 5.37). New complementary analyses recently reported ([@b79-vhrm-4-0991]) have provided important data on the clinical utility of fenofibrate in mixed dyslipidemia: in the subgroup of 2,014 patients with low HDL-C and TG \> 200 mg/dL, fenofibrate treatment induced a significant reduction of CVD events (13.5% in the fenofibrate group versus 17.8% in the placebo group, HR 0.74, p = 0.007). This highly significant effect corresponds to a 4.3% absolute risk reduction, with a number need to treat of 23 to avoid 1 or more CVD events. The beneficial effect of fenofibrate on macrovascular events appears larger among type 2 diabetic subjects with mixed dyslipidemia ([@b79-vhrm-4-0991]).

Fenofibrate was generally well tolerated. A meta-analysis of 53 trials using fibrates has not shown any increase in non coronary death or cancer ([@b10-vhrm-4-0991]). The most frequent adverse effects were gastrointestinal symptoms, skin reactions and musculoskeletal symptoms ([@b10-vhrm-4-0991]). Some cases of liver function test and creatine phosphokinase abnormalities have been reported ([@b52-vhrm-4-0991]; [@b51-vhrm-4-0991]). In the FIELD trial, it has been also observed a slight but significant increase in pancreatitis (0.8% in fenofibrate group versus 0.5% in placebo group) and pulmonary embolism (1.1% versus 0.7%), and a non significant increase in deep vein thrombosis (1.4% versus 1.0%). The excess of pancreatitis may be due to the increased lithogenicity of bile. The increased risk of venous thrombotic events may be related to the increased homocysteine level, a risk factor for thrombosis ([@b91-vhrm-4-0991]). Overall, in FIELD, rhabdomyolysis only occurred in three fenofibrate recipients and one placebo recipient, and all cases were fully resolved.

Fenofibrate is contraindicated in patients with hepatic or several renal dysfunction, pre-existing gallbladder disease, primary biliary cirrhosis or unexplained persistent liver function abnormalities. Fenofibrate potentiates the anticoagulant activity of coumarin and there is a warning on the concomitant use of fenofibrate and cyclosporine.

Clinical efficacy in combination with statins
---------------------------------------------

Guidelines suggest both fibrates and niacin as additions to statin therapy in high risk patients with persistently low levels of HDL-C and elevated triglycerides ([@b42-vhrm-4-0991]; [@b12-vhrm-4-0991]; [@b88-vhrm-4-0991]). Updated guidelines from the NCEP ATP III recognize the potential of the statin-fibrate and statin-niacin combination therapies in patients with mixed dyslipidemia and CHD or CHD risk equivalents ([@b83-vhrm-4-0991]).

Given the complementary pharmacologic profiles of fibrates and statins, greater clinical benefit may be expected with combination therapy. However the use of fibrate/statin combination therapy has been rapidly restricted due to safety concerns, mainly an increased risk of myopathy and rhabdomyolysis ([@b80-vhrm-4-0991]; [@b28-vhrm-4-0991]). Several reviews have examined the beneficial effects and the safety of a statin-fibrate combination therapy ([@b80-vhrm-4-0991]; [@b28-vhrm-4-0991]; [@b94-vhrm-4-0991]; [@b82-vhrm-4-0991]; [@b19-vhrm-4-0991]). In summary, the available evidence on safety clearly indicates differences in the risk of myopathy and rhabdomyolysis between fibrates ([@b2-vhrm-4-0991]; [@b48-vhrm-4-0991]). In combination with a statin, rhabdomyolysis has been reported to be 15-fold ([@b48-vhrm-4-0991]) and 33-fold ([@b2-vhrm-4-0991]) higher with gemfibrozil than with fenofibrate. Moreover the risk was particularly elevated when cerivastatin was use in combination with gemfibrozil ([@b15-vhrm-4-0991]; [@b41-vhrm-4-0991]; [@b48-vhrm-4-0991]). The pharmacokinetic interactions between statins and fibrates have been carefully studied ([@b73-vhrm-4-0991]; [@b19-vhrm-4-0991]). The mechanism for the higher rate of adverse interaction of gemfibrozil versus fenofibrate with statins appears mainly to be interference with statin glucuronidation by gemfibrozil. In vitro studies have demonstrated that gemfibrozil interacts with the same family of glucuronidation enzymes that are involved in statin metabolism ([@b73-vhrm-4-0991], [@b72-vhrm-4-0991]). In contrast, fenofibrate was metabolized by different glucuronidation enzymes than those involved in statin metabolism ([@b72-vhrm-4-0991]). Therefore, gemfibrozil causes a 2- to 6-fold increase in the statin AUC ([@b19-vhrm-4-0991]). But fenofibrate has not significant effect on the pharmacokinetics of various statins ([@b69-vhrm-4-0991]; [@b61-vhrm-4-0991]; [@b8-vhrm-4-0991], [@b46-vhrm-4-0991]). Finally, clinical trial data have not reported an increased risk of myopathy with various statins combined to fenofibrate ([@b26-vhrm-4-0991]; [@b30-vhrm-4-0991]; [@b4-vhrm-4-0991]; [@b61-vhrm-4-0991]; [@b93-vhrm-4-0991]; [@b25-vhrm-4-0991]; [@b44-vhrm-4-0991]). In FIELD, among the 944 patients taking fenofibrate and statin combination therapy in about 2000 patient-years of use, no cases of rhabdomyolysis were reported ([@b87-vhrm-4-0991]; [@b53-vhrm-4-0991]).

All these data suggest that fenofibrate may be the preferred fibrate for use in combination with statin and guidelines recommend fenofibrate as the fibrate of choice for high-risk statin-treated patients with mixed dyslipidemia ([@b43-vhrm-4-0991]). Fenofibrate may be added to a statin when mixed dyslipidemia responds inadequately with monotherapy, although use of lower statin doses has been recommended in this case ([@b21-vhrm-4-0991]).

The results of clinical studies support the efficacy of fenofibrate-statin therapy in patients with mixed dyslipidemia ([@b26-vhrm-4-0991]; [@b4-vhrm-4-0991]; [@b93-vhrm-4-0991]; [@b25-vhrm-4-0991]; [@b44-vhrm-4-0991]). For example, in the SAFARI trial ([@b44-vhrm-4-0991]), 619 patients with mixed dyslipidemia (TG from 150 to 500 mg/dL and LDL-C higher than 130 mg/dL) were treated with either simvastatin 20 mg/d or the combination of simvastatin 20 mg/d plus fenofibrate 160 mg/d for 12 weeks. The combined treatment was associated with significantly greater changes compared with simvastatin alone in TG (--43.0% versus --20.1%), LDL-C (--31.2% versus --25.8%), non-HDL-C (--35.3% versus --26.1%), and HDL-C (+18.6% versus +9.7%). In addition, combination therapy induced a significant shift from small, dense LDL particles to larger, more buoyant LDL particles ([@b44-vhrm-4-0991]).

The same beneficial effect on LDL subfractions has been observed in the DIACOR study in the group of patients with type 2 diabetes and mixed dyslipidemia receiving the combination of simvastatin 20 mg/d and fenofibrate 160 mg/d ([@b62-vhrm-4-0991]). The DIACOR trial has also shown that combination therapy has greater anti-inflammatory effects than either form of monotherapy ([@b65-vhrm-4-0991]), probably in relation with the cross-talk between statins and PPARα agonists regarding pleiotropic effects ([@b70-vhrm-4-0991]). Several trials are ongoing to evaluate more precisely the complementary beneficial effects of fenofibrate for patients with mixed dyslipidemia not at goals on statin therapy.

All these data may support the use of fenofibrate-statin combination therapy to achieve a global lipid and vascular control and suggest that atherosclerosis and CVD benefits may be greater with combination therapy, but direct evidence of these benefits is not yet available. Hopefully, the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study was designed to evaluate whether adding fenofibrate to simvastatin can reduce CVD risk beyond the risk reduction with simvastatin alone in type 2 diabetic patients ([@b86-vhrm-4-0991]; [@b38-vhrm-4-0991]).

Clinical efficacy in combination therapy with other agents
----------------------------------------------------------

Although statins are the drug of first choice in patients with mixed dyslipidemia, the use of statins may be limited by intolerance or poor response in monotherapy.

In patients who are unable to tolerate statin therapy, two alternative combination therapies with fenofibrate can be proposed at patients with mixed dyslipidemia, either fenofibrate-ezetimibe or fenofibrate-colesevelam. The efficacy and safety of fenofibrate plus ezetimibe combination therapy has been evaluated in 625 patients with mixed dyslipidemia \[TG from 200 to 500 mg/dL, LDL-C from 130 to 220 mg/dL (100--180 mg/dL in patients with diabetes)\] ([@b31-vhrm-4-0991]; [@b57-vhrm-4-0991]) randomized to received one of the four daily treatments: placebo, ezetimibe 10 mg, fenofibrate 160 mg and fenofibrate 160 mg + ezetimibe 10 mg during 12 weeks. The complementary effects of fenofibrate and ezetimibe improve the overall atherogenic lipid profile, with decreases in LDL-C of 20.4%, non-HDL-C of 30.4%, TG of 44.0%, and increase in HDL-C of 19.0% ([@b31-vhrm-4-0991]). Moreover, the co-administration of fenofibrate and ezetimibe produced complementary and favorable changes in lipoprotein subfractions, promoting a shift in the LDL particle distribution profile toward larger, more buoyant particles ([@b31-vhrm-4-0991]; [@b89-vhrm-4-0991]). After completing the 12-week, randomized, double-blind base study, 576 patients entered in a 48-week, double-blind extension study, during which they received fenofibrate or fenofibrate plus ezetimibe ([@b57-vhrm-4-0991]). Improvements from baseline in LDL-C (--22.0% versus --8.6%), non-HDL-C (--31.6% versus --19.4%), TG (--46.0% versus --41.8%) and HDL-C (20.9% versus 17.8%) levels were significantly greater with fenofibrate-ezetimibe combination therapy than with fenofibrate alone. The combination of ezetimibe plus fenofibrate was well tolerated during both the base study ([@b31-vhrm-4-0991]) and the extension study ([@b57-vhrm-4-0991]). In the base study, one patient receiving combination therapy was discontinued after being diagnosed with cholelithiasis and subsequent cholecystectomy. In the extension study, the proportion of patients with cholecystectomy was not significantly different between treatments, but this study was not designed to assess this infrequent biliary adverse event. It has been reported that fenofibrate may increase cholesterol excretion into bile and ezetimibe has inconsistent effects on biliary cholesterol in animal models ([@b29-vhrm-4-0991]).

Another alternative to statin therapy is a bile acid sequestrant (BAS) combined with a fibrate. Colesevelam has become the preferred BAS because it is well-tolerated compared to older BAS and lowers LDL-C levels an average of 15% to 18%. The complementary efficacy of colesevelam added to fenofibrate has been evaluated in 129 patients with mixed dyslipidemia treated 8 weeks by fenofibrate 160 mg/d, then randomized to receive either colesevelam 3.75 g/d or placebo ([@b58-vhrm-4-0991]). Compared with fenofibrate monotherapy, the combination of fenofibrate and colesevelam significantly reduced LDL-C (--17.0%) and non-HDL-C (--21.0%) from baseline, without affecting the TG-lowering or HDL-C raising effects of fenofibrate ([@b58-vhrm-4-0991]).

Finally in patients with severe mixed dyslipidemia or poor responders to statin monotherapy, a new option is a triple therapy using statin, ezetimibe and fenofibrate. The efficacy of the co-administration of ezetimibe/simvastatin 10/20 mg + fenofibrate 160 mg has been evaluated in 611 patients with mixed dyslipidemia (TG from 150 to 500 mg/dL, LDL-C from 130 to 220 mg/dL \[100--180 mg/dL in patients with diabetes\]) randomized to receive one of the four treatments ezetimibe/simvastatin 10/20 mg + fenofibrate 160 mg, ezetimibe 10/20 mg, fenofibrate 160 mg, or placebo for 12 weeks ([@b32-vhrm-4-0991]). The triple therapy improved the overall atherogenic lipid profile (--46% for LDL-C, --50% for TG and non-HDL-C, --45% for ApoB, +19% for HDL-C) with a significant shift of small, dense LDL to larger particles ([@b32-vhrm-4-0991]). Although the co-administration of fenofibrate and ezetimibe/simvastatin was well tolerated in this short-term study, the long-term safety and clinical outcome benefits remain to be determined.

Rational prescribing of fenofibrate in mixed dyslipidemias
==========================================================

Although statins are indicated as first-line therapy for patients with mixed dyslipidemia, statin treatment may be limited by the failure to reach LDL-C and non-HDL-C targets and by intolerance or poor-response in monotherapy. Moreover, many patients remain at risk of CVD despite having LDL-C levels below recommended targets. Thus, increasing attention is being focused on other lipoprotein fractions such as HDL and triglycerides, as potential targets of therapy. There is recent evidence that abnormalities of the triglyceride-HDL axis are especially associated with adverse cardiovascular outcomes. In FIELD, fenofibrate reduced CVD effectively in patients with insulin resistance, low HDL-C, and high TG. However, prescribing recommendations are constrained by a lack of clinical trial evidence of fenofibrate-statin therapy. Nevertheless, it is possible to propose a rational prescribing of fenofibrate in mixed dyslipidemia: For high-risk patients not at their non-HDL-C goals and with high TG and/or low HDL-C levels, a statin-fenofibrate combination therapy can be required to control all lipid abnormalities. In light of the increasing prevalence of diabetes and the metabolic syndrome, the clinical use of fenofibrate combined with a statin may be likely to increase. Data from prospective outcome studies are required to evaluate the benefits of this approach.In severe mixed dyslipidemia, when the LDL-C and non-HDL-C goals are not reached with a usual dose of statin and fenofibrate, a triple therapy with a statin, fenofibrate, and ezetimibe can be used to avoid the highest statin doses and with the same caution as statin-fenofibrate therapy.For patients with intolerance to statin therapy or if a statin is inappropriate or contraindicated, fenofibrate monotherapy is indicated in mixed dyslipidemia. However, particularly for high risk patients, the LDL-C and/or non-HDL-C goals are often not attained with fenofibrate alone. A combination of fenofibrate wth ezetimibe or colesevelam can be useful for these patients.

In conclusion, despite the impressive benefits achieved by LDL-C lowering using statins, there are compelling reasons to consider other lipoprotein abnormalities present in mixed dyslipidemia as risk factors. Fenofibrate has a favorable effect on the global atherogenic lipoprotein profile and may offer important treatment alternatives as second-line therapy.
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